Clinical trial
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
NCT00327600 · AmpliMed Corporation, Industry · Completed
Key facts
| NCT number | NCT00327600 |
|---|---|
| Title | Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma |
| Official title | A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma |
| Lead sponsor | AmpliMed Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | imexon, DTIC |
| Enrollment | 68 |
| Start date | Jul 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 18, 2006 |
| Last update posted | Sep 15, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: